Tansey to retire from Inspire board
By HME News Staff
Updated 10:23 AM CDT, Wed July 22, 2026
MINNEAPOLIS – Casey M. Tansey will retire from the Inspire Medical Systems board of directors after more than 18 years of service, effective July 30. “As one of the first venture investors to recognize the potential impact of Inspire therapy for patients with OSA, Mr. Tansey has provided valuable mentorship, leadership and perspective throughout the company’s founding, initial public offering and subsequent growth,” said Tim Herbert, chairman and CEO of Inspire. Tansey represented U.S. Venture Partners and led Inspire’s Series A financing in November 2007. He has served on the board since that time. Inspire develops and commercializes minimally invasive treatments for obstructive sleep apnea (OSA). The company says its proprietary Inspire therapy is the first neurostimulation technology approved by the U.S. Food and Drug Administration (FDA), EU Medical Device Regulation (EU MDR) and PDMA that provides a safe and effective treatment for moderate to severe OSA. The company expects to announce a new director to replace Tansey in the near future.
Comments